Listing Review initiated by the Toronto Stoc... ( TORONTO Nov. 3 / Predictive medic...)

Listing Review initiated by the Toronto Stock Exchange

Date:11/3/2008

TORONTO, Nov. 3 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced it has been notified by the Toronto Stock Exchange ("TSX") that it is reviewing the eligibility of the Company's common shares for continued listing on the TSX.

The Company is being reviewed under the TSX's Remedial Review Process and has been granted 210 days to comply with all requirements for continued listing. If the Company cannot demonstrate that it meets all TSX listing requirements on or before June 2, 2009, the Company's common shares will be delisted 30 days from such date. A meeting of the TSX's Listings Committee is scheduled to be held on May 28, 2009 to consider whether to delist the common shares of the Company. The TSX has also advised that, if the TSX becomes aware of additional negative developments such that the continued trading or listing of the Company's shares is contrary to the public interest, an expedited listing review could be initiated.

Over the next months, while the Company awaits their FDA appeal decision and other corporate developments, PreMD will evaluate its options in dealing with the TSX and will provide updates as they become available.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include PREVU* POC and PREVU* LT, both non-invasive skin cholesterol tests. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks a
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Standard Management Announces OTCBB Listing
2. Pharsight Files Application for Nasdaq Capital Market Listing
3. InfoLogix Announces Approval for NASDAQ Listing
4. AKELA Pharma Inc. announces U.S. public offering and proposed listing
5. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
6. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
7. Cash Technologies Discusses AMEX Listing Requirements
8. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
9. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
10. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
11. Elbit Imaging Ltd. Selected for Listing on Nasdaq Global Select Market

Post Your Comments:

Listing Review initiated by the Toronto Stoc...( TORONTO Nov. 3 / Predictive medic...),Health